MARKET

DARE

DARE

Dare Bioscience
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.419
-0.041
-2.82%
Opening 11:35 06/24 EDT
OPEN
1.430
PREV CLOSE
1.460
HIGH
1.465
LOW
1.390
VOLUME
900.47K
TURNOVER
--
52 WEEK HIGH
3.850
52 WEEK LOW
0.9100
MARKET CAP
70.02M
P/E (TTM)
-1.5900
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in ConforMIS, Citius Pharmaceuticals, Clover Health, Capricor Therapeutics, or Dare Bioscience?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CFMS, CTXR, CLOV, CAPR, and DARE.
PR Newswire - PRF · 1d ago
26 Stocks Moving in Wednesday's Pre-Market Session
Gainers Acasti Pharma Inc. (NASDAQ: ACST) rose 39% to $0.75 in pre-market trading after jumping 10% on Tuesday. The company reported a narrower FY21 loss.
Benzinga · 1d ago
Sanderson Farms, GameStop among notable premarket gainers
vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera
Seekingalpha · 2d ago
Is Dare Bioscience, Inc. (DARE) A Good Stock To Buy?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to ...
Insider Monkey · 06/15 16:53
Daré Bioscience to Present at 2021 BIO Digital
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a company presentation at 2021 BIO Digital, being held virtually June 10-11 and 1...
GlobeNewswire · 06/04 12:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Zosano Pharma (NASDAQ:ZSAN) stock rose 22.29% to $0.91 during Wednesday's after-market session. This security traded at a volume of 1.8 million shares come close, making up 69.15% of its average volume over the last 100 days. The company's market c...
Benzinga · 05/26 20:46
Dare Bioscience Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Dare Bioscience Inc (NASDAQ:DARE) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 05/13 18:33
Dare Bioscience EPS beats by $0.09
Dare Bioscience (DARE): Q1 GAAP EPS of -$0.16 beats by $0.09.Cash and cash equivalents: $7.7 million at March 31, 2021, compared to $4.7 million at December 31, 2020.Press Release
Seekingalpha · 05/13 12:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DARE. Analyze the recent business situations of Dare Bioscience through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DARE stock price target is 5.00 with a high estimate of 9.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 3.62M
% Owned: 7.33%
Shares Outstanding: 49.35M
TypeInstitutionsShares
Increased
6
348.84K
New
9
231.81K
Decreased
8
1.70M
Sold Out
5
238.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.48%
Pharmaceuticals & Medical Research
+1.10%
Key Executives
Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Secretary/Director
Sabrina Johnson
Chief Financial Officer
Gregg Beloff
Chief Financial Officer
Lisa Walters-Hoffert
Chief Accounting Officer/Controller/Treasurer
Jame O'Neill
Other
John Fair
Director
Sophia Ononye-Onyia
Independent Director
Cheryl Blanchard
Independent Director
Jessica Grossman
Independent Director
Steve Hall
Independent Director
Susan Kelley
Independent Director
Gregory Matz
Independent Director
Robin Steele
No Data
  • All
  • Financials
  • Insiders
More
About DARE
Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Webull offers kinds of Dare Bioscience Inc stock information, including NASDAQ:DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.